Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma(NIVAHL) | completed | Phase 2 | 110 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT02852486 | Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response(EDI-PIO) | completed | Phase 2 | 31 | University of Campinas, BrazilOTHER | 1 | Mar 30, 2025 |
| clinicaltrials |
| NCT03700450 | Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 37 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03442673 | Chemotherapy and G-CSF for Mobilization(MOCCCA) | completed | Phase 2 | 137 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02744612 | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 39 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03690115 | Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients(PONALLO) | completed | Phase 2 | 23 | Versailles HospitalOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT01518556 | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia(IDAML) | completed | Phase 1 / Phase 2 | 49 | Konkuk University Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2025 | clinicaltrials |
| NCT04939844 | REST - Replacing Steroids in the Transplant Ineligble(REST) | completed | Phase 2 | 51 | Oslo University HospitalOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT02193958 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 55 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT02506959 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03235544 | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor((CITADEL-205)) | completed | Phase 2 | 162 | Incyte CorporationINDUSTRY | 11 | Mar 18, 2025 | clinicaltrials |
| NCT01804985 | De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia(DESTINY) | completed | Phase 2 | 174 | University of LiverpoolOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03126019 | A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma(CITADEL-203) | completed | Phase 2 | 126 | Incyte CorporationINDUSTRY | 13 | Mar 14, 2025 | clinicaltrials |
| NCT05454241 | CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies | completed | Phase 2 | 14 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02924272 | Ixazomib Rollover Study | completed | Phase 2 | 32 | TakedaINDUSTRY | 11 | Mar 12, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03372057 | A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)(PRIMO) | completed | Phase 2 | 156 | SecuraBioINDUSTRY | 5 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01420770 | Phase 2 Study of SAR302503 in Patients With Myelofibrosis | completed | Phase 2 | 30 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01420783 | Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 81 | Bristol-Myers SquibbINDUSTRY | 9 | Mar 5, 2025 | clinicaltrials |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | completed | Phase 2 | 25 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02484430 | Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01437709 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant | completed | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT01701986 | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03770416 | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03744676 | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | completed | Phase 2 | 104 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05844956 | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) | completed | Phase 1 / Phase 2 | 17 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03839446 | Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | completed | Phase 2 | 16 | Robert Redner, MDOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02824029 | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 28 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG)(MyDRUG) | completed | Phase 1 / Phase 2 | 103 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03443128 | Vinorelbine for Recurrent ALCL-2017 | completed | Phase 2 | 20 | Children's Cancer Group, ChinaNETWORK | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03792763 | Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients(DEFENCE) | completed | Phase 2 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Feb 11, 2025 | clinicaltrials |
| NCT02927769 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment(CheckMate 744) | completed | Phase 2 | 72 | Bristol-Myers SquibbINDUSTRY | 11 | Feb 10, 2025 | clinicaltrials |
| NCT04102150 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | completed | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03398200 | Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma | completed | Phase 2 | 99 | Omar AljitawiOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03992339 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma(SEARCH) | completed | Phase 2 | 60 | Antengene CorporationINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03209973 | A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Feb 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2025source: clinicaltrials